CYAD Stock Overview
A biopharmaceutical company, focuses on the research and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Celyad Oncology SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.45 |
| 52 Week High | €1.22 |
| 52 Week Low | €0.21 |
| Beta | 1.36 |
| 1 Month Change | -36.87% |
| 3 Month Change | 52.37% |
| 1 Year Change | 12.09% |
| 3 Year Change | -86.34% |
| 5 Year Change | -95.50% |
| Change since IPO | -97.30% |
Recent News & Updates
Shareholder Returns
| CYAD | BE Biotechs | BE Market | |
|---|---|---|---|
| 7D | -6.7% | 0.8% | 2.1% |
| 1Y | 12.1% | 19.1% | 3.8% |
Return vs Industry: CYAD underperformed the Belgian Biotechs industry which returned 16.9% over the past year.
Return vs Market: CYAD exceeded the Belgian Market which returned 2.1% over the past year.
Price Volatility
| CYAD volatility | |
|---|---|
| CYAD Average Weekly Movement | 34.9% |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 3.7% |
| 10% most volatile stocks in BE Market | 7.1% |
| 10% least volatile stocks in BE Market | 2.0% |
Stable Share Price: CYAD's share price has been volatile over the past 3 months compared to the Belgian market.
Volatility Over Time: CYAD's weekly volatility has increased from 19% to 35% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 18 | Matt Kane | www.celyad.com |
Celyad Oncology SA, a biopharmaceutical company, focuses on the research and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. The company is developing shRNA non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the TCR without the need for gene editing; multi-specific CAR T-cell platform that focuses on the NKG2D receptor; NKG2D-based CAR T-cell therapies; and B7-H6 targeting CAT T-cell therapies. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery/PerkinElmer for the use of its shRNA reagents to reduce expression of one or more defined targets.
Celyad Oncology SA Fundamentals Summary
| CYAD fundamental statistics | |
|---|---|
| Market cap | €18.91m |
| Earnings (TTM) | -€7.75m |
| Revenue (TTM) | €72.00k |
258.6x
P/S Ratio-2.4x
P/E RatioIs CYAD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CYAD income statement (TTM) | |
|---|---|
| Revenue | €72.00k |
| Cost of Revenue | €34.00k |
| Gross Profit | €38.00k |
| Other Expenses | €7.79m |
| Earnings | -€7.75m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Apr 04, 2025
| Earnings per share (EPS) | -0.19 |
| Gross Margin | 52.78% |
| Net Profit Margin | -10,766.67% |
| Debt/Equity Ratio | 0% |
How did CYAD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/30 04:15 |
| End of Day Share Price | 2025/01/30 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Celyad Oncology SA is covered by 16 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Olga Smolentseva | Bryan Garnier & Co |
| John Savin | Edison Investment Research |
| Edward White | H.C. Wainwright & Co. |